恆指26,300失而復得 匯控等銀行股捱沽 惟小米及藥明生物升逾4%再破頂
雖然美國國會兩黨就9,000億美元抗疫新刺激方案達成協議，方案包括延長額外失業救濟及向大多數美國民眾「派錢」等。不過，美股期貨先彈後回，藍籌股指期貨倒跌，其中道指期貨由最高30,333，掉頭低見30,078，現造30,110，倒跌3點；但納指期貨回升0.2%。
亞洲多國疫情反彈，亞太區股市今早普遍反覆受壓，但跌幅均少1%，其中日經高見26,905再創逾29年半高遇阻曾低見26,533，現造26,601，續吐0.6%。不過，滬指及深成逆市反覆回升近0.5%及1%，分別報3,410及13,985。
美國商務部上周五(18日)以保護美國國家安全和外交利益為由，將包括中芯(00981.HK)等60多間中資企業列入實體清單；加上本港疫情仍然嚴峻，恆指延續上周五回吐勢，今早低開75點報26,422，跌幅曾擴至223點低見26,274獲承接，現造26,424，跌73或不足0.3%，成交額額396億元。
藍籌股普遍受壓，銀行股無一倖免，尤其是匯控(00005.HK)低見39.65元，現造39.75元，續跌3.4%；中銀(02388.HK)三連跌，報23.25元，續跌1.7%。相反，三大保險股反覆向好，其中友邦(01299.HK)扭兩連跌，股價重越10天線，報90.3元，回升0.9%。
地產股以恆隆地產(00101.HK)、新世界(00017.HK)、潤地(01109.HK)及中海外(00688.HK)跌幅最大，分別報19.2元、36.7元、30.85元及17.52元，跌1.7%-2.1%。此外，上周五急漲中移動(00941.HK)及聯通(00762.HK)回吐2.7%及2.9%，分別報44.35元及4.43元，前者重失10天及20天線，後者重失20天線。
騰訊(00700.HK)及阿里巴巴(09988.HK)續跌逾1%，分別低見571.5元及251.6元。不過，小米(01810.HK)繼上周五整固後，今早反覆再破頂，報30元即市高位，回升4.2%。安踏(02020.HK)扭兩連跌，股價重越20天及10天線(108.7元及109元)，最高見109.3元，現造109元，回升3.7%。此外，藥明生物(02269.HK)升破上周尾所創紀錄高位88元，報91元，續升近4.1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
